Proteins & Adjuvants
Protein Manufacturing
Hawaii Biotech has the capability to produce high-quality purified proteins to support its vaccine development programs and the research and development of drugs and biologicals by pharmaceutical and biotech companies.
Our proven, proprietary S-2 recombinant protein production platform with special expertise in multiple protein vaccines and driven by multiple generations of advanced and efficient proprietary vectors form the core of our in-house cGMP production capabilities. We use stably transformed insect cells as a platform to rapidly and reproducibly produce high quality antigens at lower cost through the use of disposable systems, with consistently competitive medium to very high yields.
Use of disposable systems reduces requirements for infrastructure and cleaning that results in significant reduction of manufacturing cost. Hawaii Biotech proteins exhibit proper folding/structure, consistent glycosylation and good immunogenicity.
Protein Manufacturing
Hawaii Biotech has the capability to produce high-quality purified proteins to support its vaccine development programs and the research and development of drugs and biologicals by pharmaceutical and biotech companies.
Our proven, proprietary S-2 recombinant protein production platform with special expertise in multiple protein vaccines and driven by multiple generations of advanced and efficient proprietary vectors form the core of our in-house cGMP production capabilities. We use stably transformed insect cells as a platform to rapidly and reproducibly produce high quality antigens at lower cost through the use of disposable systems, with consistently competitive medium to very high yields.
Use of disposable systems reduces requirements for infrastructure and cleaning that results in significant reduction of manufacturing cost. Hawaii Biotech proteins exhibit proper folding/structure, consistent glycosylation and good immunogenicity.
Adjuvants
Hawaii Biotech has acquired rights to a number of novel adjuvants, including its semi-synthetic saponin-based GPI-0100 used in a variety of formulations, suitable for parenteral and mucosal administration.
GPI-0100 has been utilized in several third-party clinical trials of prophylactic and therapeutic vaccine candidates. The company maintains an active Drug Master File on GPI-0100.
In addition to use in our own vaccine candidates, HBI makes its adjuvants available to third parties for license with specific product formulations.
Adjuvants
Hawaii Biotech has acquired rights to a number of novel adjuvants, including its semi-synthetic saponin-based GPI-0100 used in a variety of formulations, suitable for parenteral and mucosal administration.
GPI-0100 has been utilized in several third-party clinical trials of prophylactic and therapeutic vaccine candidates. The company maintains an active Drug Master File on GPI-0100.
In addition to use in our own vaccine candidates, HBI makes its adjuvants available to third parties for license with specific product formulations.